Stockreport

ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF promising Phase 2 QUILT-3.055 trial results at the IASLC World Conference on Lung Cancer, showing that ANKTIVA significantly reverses lymphopenia in advanced NSCLC patie [Read more]